Monthly Prescribing Reference

FDA Clears VNS Device for Paroxysmal Hemicrania, Hemicrania Continua

Patients treated with gammaCore experienced clinically meaningful benefits. The Food and Drug Administration has granted 510(k) clearance to expand the approval of gammaCore TM to include the ...
Yahoo Finance

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

ROCKAWAY, NJ, Sept. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received ...
Nasdaq

electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England

ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled ...
Yahoo Finance

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only ...
Nasdaq

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for ...
International Business Times

Facial pain often severe, but not common

The various forms of recurrent facial pain can sometimes be debilitating, but are fortunately relatively uncommon, according to a new study. There are a number of painful syndromes affecting the face ...